Skip to content

Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)

Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01208909
Enrollment
40
Registered
2010-09-24
Start date
2009-08-31
Completion date
2011-12-31
Last updated
2010-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

In the treatment of glioblastoma (GBM) neurosurgical resection of the tumor is usually considered a a first step of effective therapy. Radical resection of the tumor is highly beneficial to the patient as measured in progression-free survival and overall survival. At the same time eloquent areas of the brain have to remain intact to preserve quality of life. Both 5-ALA fluorescence and intraoperative MRI are used for intraoperative marking of tumor tissue and thereby to improve precision of GBM-Resection. We now study whether the combination of 5-ALA fluorescence and intraoperative MRI increases the number of sites where tumor tissue can be detected. \- Trial with surgical intervention

Detailed description

Precision of GBM-Resection Intraoperative marking of tumor tissue Combination of 5-ALA fluorescence and intraoperative MRI

Interventions

PROCEDUREdiagnostic 5-ALA and MRI for tumor resection

diagnostic 5-ALA and MRI for tumor resection

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients with Glioblastoma multiforme (GBM) * no other tumor types or metastases

Exclusion criteria

* Allergy against 5-ALA or Porphyrin * Porphyria * Pregnancy

Countries

Switzerland

Contacts

Primary ContactRené L. Bernays, MD
+41 (0)44 255 11 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026